October 20, 2020
1 min read
Save
ELDERCARE-AF
Issue: October 2020
Low-dose edoxaban (Savaysa, Daiichi Sankyo) vs. placebo for prevention of stroke and systemic embolism in patients aged at least 80 years with AF.
